{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T15:26:17Z","timestamp":1789140377383,"version":"build-2803163510"},"reference-count":35,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"GSK"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1136\/ijgc-2022-003492","type":"journal-article","created":{"date-parts":[[2022,8,16]],"date-time":"2022-08-16T12:06:17Z","timestamp":1660651577000},"page":"1250-1257","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Patient-reported outcomes in the GARNET trial in patients with advanced or recurrent mismatch repair-deficient\/microsatellite instability-high endometrial cancer treated with dostarlimab"],"prefix":"10.1016","volume":"32","clinical-trial-number":[{"clinical-trial-number":"nct02715284","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02715284","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02715284","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02715284","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02715284","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02715284","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Rebecca","family":"Kristeleit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cara","family":"Mathews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres","family":"Redondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Boklage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Hanlon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellie","family":"Im","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jubilee","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ijgc-2022-003492_bb0010","first-page":"7","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1136\/ijgc-2022-003492_bb0015","doi-asserted-by":"crossref","first-page":"90532","DOI":"10.18632\/oncotarget.20042","article-title":"Checkpoint inhibitors in endometrial cancer: preclinical rationale and clinical activity","volume":"8","author":"Mittica","year":"2017","journal-title":"Oncotarget"},{"key":"10.1136\/ijgc-2022-003492_bb0020","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ejogrb.2012.10.028","article-title":"Increased incidence and improved survival in endometrioid endometrial cancer diagnosed since 1989 in the Netherlands: a population based study","volume":"166","author":"Boll","year":"2013","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1136\/ijgc-2022-003492_bb0025","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1200\/JCO.2002.08.171","article-title":"Phase II trial of the pegylated liposomal doxorubicin in previously treated metastatic endometrial cancer: a Gynecologic Oncology Group study","volume":"20","author":"Muggia","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2022-003492_bb0030","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.ygyno.2006.03.043","article-title":"Phase II study of oxaliplatin as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study","volume":"103","author":"Fracasso","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2022-003492_bb0035","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.1200\/JCO.2008.20.6995","article-title":"Phase II trial of ixabepilone as second-line treatment in advanced endometrial cancer: gynecologic Oncology Group trial 129-P","volume":"27","author":"Dizon","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2022-003492_bb0040","first-page":"258","article-title":"Current recommendations and recent progress in endometrial cancer","volume":"69","author":"Brooks","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"10.1136\/ijgc-2022-003492_bb0045","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Cancer Genome Atlas Research Network","year":"2013","journal-title":"Nature"},{"key":"10.1136\/ijgc-2022-003492_bb0050","article-title":"Epidemiology of microsatellite instability high (MSI-H) and deficient mismatch repair (dMMR) in solid tumors: a structured literature review","volume":"1807929","author":"Lorenzi","year":"2020","journal-title":"J Oncol"},{"key":"10.1136\/ijgc-2022-003492_bb0055","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-019-0738-1","article-title":"Mismatch repair deficiency\/microsatellite instability-high as a predictor for anti-PD-1\/PD-L1 immunotherapy efficacy","volume":"12","author":"Zhao","year":"2019","journal-title":"J Hematol Oncol"},{"key":"10.1136\/ijgc-2022-003492_bb0060","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/cncr.31901","article-title":"Mismatch repair deficiency identifies patients with high-intermediate-risk (HIR) endometrioid endometrial cancer at the highest risk of recurrence: a prognostic biomarker","volume":"125","author":"Backes","year":"2019","journal-title":"Cancer"},{"key":"10.1136\/ijgc-2022-003492_bb0065","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1093\/annonc\/mdz116","article-title":"ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1\/PD-L1 expression and tumour mutational burden: a systematic review-based approach","volume":"30","author":"Luchini","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2022-003492_bb0070","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.trecan.2016.02.004","article-title":"The immune biology of microsatellite-unstable cancer","volume":"2","author":"Kloor","year":"2016","journal-title":"Trends Cancer"},{"key":"10.1136\/ijgc-2022-003492_bb0075","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1634\/theoncologist.2016-0046","article-title":"Mismatch repair deficiency and response to immune checkpoint blockade","volume":"21","author":"Lee","year":"2016","journal-title":"Oncologist"},{"key":"10.1136\/ijgc-2022-003492_bb0080","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1001\/jamaoncol.2015.2151","article-title":"Association of polymerase e-mutated and microsatellite-instable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1","volume":"1","author":"Howitt","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1136\/ijgc-2022-003492_bb0085","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1158\/2159-8290.CD-14-0863","article-title":"The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints","volume":"5","author":"Llosa","year":"2015","journal-title":"Cancer Discov"},{"key":"10.1136\/ijgc-2022-003492_bb0090","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1158\/1078-0432.CCR-15-1678","article-title":"Microsatellite instability as a biomarker for PD-1 blockade","volume":"22","author":"Dudley","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1136\/ijgc-2022-003492_bb0095","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1001\/jamaoncol.2020.4515","article-title":"Clinical activity and safety of the anti-programmed death 1 monoclonal antibody dostarlimab for patients with recurrent or advanced mismatch repair-deficient endometrial cancer: a nonrandomized phase 1 clinical trial","volume":"6","author":"Oaknin","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1136\/ijgc-2022-003492_bb0100","unstructured":"ClinicalTrials.gov . Study of TSR-042, an anti-programmed cell death-1 receptor (PD-1) monoclonal antibody, in participants with advanced solid tumors (garnet). Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02715284 [Accessed 01 Sep 2021]."},{"key":"10.1136\/ijgc-2022-003492_bb0105","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.3_suppl.9","article-title":"Safety and efficacy of anti\u2013PD-1 antibody dostarlimab in patients (pts) with mismatch repair-deficient (dMMR) solid cancers: results from GARNET study","volume":"39","author":"Andre","year":"2021","journal-title":"JCO"},{"key":"10.1136\/ijgc-2022-003492_bb0110","article-title":"Garnet: preliminary safety, efficacy, pharmacokinetic, and biomarker characterization from a phase 1 clinical trial of TSR-042 the (anti-PD-1 monoclonal antibody), TSR-042, in patients with recurrent\/or advanced NSCLC","volume":"6","author":"Perez","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1136\/ijgc-2022-003492_bb0115","author":"European Medicines Agency","year":"2021","journal-title":"Jemperli"},{"key":"10.1136\/ijgc-2022-003492_bb0120","unstructured":"GSK . Jemperli. Available: https:\/\/gskpro.com\/content\/dam\/global\/hcpportal\/en_US\/Prescribing_Information\/Jemperli\/pdf\/JEMPERLI-PI-MG.PDF [Accessed 01 Sep 2021]."},{"key":"10.1136\/ijgc-2022-003492_bb0125","unstructured":"US Food and Drug Administration . FDA grants accelerated approval to dostarlimab-gxly for dMMR advanced solid tumors. Available: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-dostarlimab-gxly-dmmr-advanced-solid-tumors [Accessed 23 Aug 2021]."},{"key":"10.1136\/ijgc-2022-003492_bb0130","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2147\/PROM.S156279","article-title":"The importance of patient-reported outcomes in clinical trials and strategies for future optimization","volume":"9","author":"Mercieca-Bebber","year":"2018","journal-title":"Patient Relat Outcome Meas"},{"key":"10.1136\/ijgc-2022-003492_bb0135","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.jval.2017.09.009","article-title":"Informing the tolerability of cancer treatments using patient-reported outcome measures: summary of an FDA and Critical Path Institute workshop","volume":"21","author":"Kluetz","year":"2018","journal-title":"Value Health"},{"key":"10.1136\/ijgc-2022-003492_bb0140","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1158\/1078-0432.CCR-15-2035","article-title":"Focusing on core patient-reported outcomes in cancer clinical trials: symptomatic adverse events, physical function, and disease-related symptoms","volume":"22","author":"Kluetz","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1136\/ijgc-2022-003492_bb0145","article-title":"2019 OCE partners in progress: patient reported outcomes \u2013 in the benefit risk assessment","author":"Kanapuru","year":"2019","journal-title":"US food and drug administration"},{"key":"10.1136\/ijgc-2022-003492_bb0150","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1097\/IGC.0000000000000245","article-title":"Quality of life research in endometrial cancer: what is needed to advance progress in this disease site? Methodological considerations from the Gynecologic Cancer InterGroup Symptom Benefit Working Group brainstorming session, Leiden 2012","volume":"24","author":"McAlpine","year":"2014","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2022-003492_bb0155","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1177\/1740774519836991","article-title":"Patient reported outcomes in anti-PD-1\/PD-L1 inhibitor immunotherapy registration trials: FDA analysis of data submitted and future directions","volume":"16","author":"King-Kallimanis","year":"2019","journal-title":"Clin Trials"},{"key":"10.1136\/ijgc-2022-003492_bb0160","doi-asserted-by":"crossref","first-page":"e565","DOI":"10.1634\/theoncologist.2018-0449","article-title":"Patient-reported outcomes with PD-1\/PD-L1 inhibitors for advanced cancer: a meta-analysis","volume":"24","author":"Nishijima","year":"2019","journal-title":"Oncologist"},{"key":"10.1136\/ijgc-2022-003492_bb0165","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jtho.2019.01.016","article-title":"Health-related quality of life in KEYNOTE-010: a phase II\/III study of pembrolizumab versus docetaxel in patients with previously treated advanced, programmed death ligand 1-expressing NSCLC","volume":"14","author":"Barlesi","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1136\/ijgc-2022-003492_bb0170","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1016\/S1470-2045(17)30690-3","article-title":"Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial","volume":"18","author":"Brahmer","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2022-003492_bb0175","doi-asserted-by":"crossref","first-page":"S1166","DOI":"10.1016\/j.annonc.2020.08.2266","article-title":"LBA36 safety and antitumor activity of dostarlimab in patients (pts) with advanced or recurrent DNA mismatch repair deficient (dMMR) or proficient (MMRp) endometrial cancer (EC): results from GARNET","volume":"31","author":"Oaknin","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2022-003492_bb0180","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1002\/cncr.21637","article-title":"Metaanalysis of the correlation between radiographic tumor response and patient-reported outcomes","volume":"106","author":"Victorson","year":"2006","journal-title":"Cancer"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X2400687X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X2400687X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ijgc-2022-003492","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T01:26:59Z","timestamp":1753234019000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X2400687X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":35,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S1048891X2400687X"],"URL":"https:\/\/doi.org\/10.1136\/ijgc-2022-003492","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient-reported outcomes in the GARNET trial in patients with advanced or recurrent mismatch repair-deficient\/microsatellite instability-high endometrial cancer treated with dostarlimab","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ijgc-2022-003492","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2022 This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, an indication of whether changes were made, and the use is non-commercial. See: http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/.","name":"copyright","label":"Copyright"}]}}